The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis

World Journal of Surgical Oncology

Ping Chen¹  Yunbao Xu²  Tong Yang³  Fengyan Zhou⁴  Derry Minyao Ng⁵  Xinyu Zhou⁶  Jiaze Hong⁶  Feifei Zhou⁶  Jieyin Jin⁶  Beilei Zhang⁶ 

[1] Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences;Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences;Department of Tumor HIFU Therapy, HwaMei Hospital, University of Chinese Academy of Sciences;Emergency Medical Center, Ningbo Yinzhou No 2 Hospital;Medical College of Ningbo University;The Second Clinical Medical College, Zhejiang Chinese Medical University;

关键词: Metastatic pancreatic cancer;    FOLFIRINOX;    Efficacy;    Safety;    Meta-analysis;   

DOI  :  10.1186/s12957-021-02291-6

来源: DOAJ

【 摘 要 】

Abstract Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients with metastatic PC still receive palliative care. Here, we report the efficacy and safety of FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, 5-fluorouracil) in the treatment of metastatic PC. Methods We searched PubMed, Web of Science, EBSCO, and Cochrane library databases for articles that described efficacy and safety of FOLFIRINOX in patients with metastatic PC, from January 1996 to July 2020. The primary outcomes targeted included overall survival (OS) and progression-free survival (PFS). Results We found that FOLFIRINOX could directly improve OS rate of patients with metastatic PC (HR 0.76, 95% Cl 0.67–0.86, p<0.001) but had no benefit on PFS. Results from subgroup analyses showed that FOLFIRINOX had superior benefits than monochemotherapy (HR 0.59, 95% Cl 0.52–0.67, p<0.001), followed by FOLFIRINOX versus combination chemotherapy (HR 0.76, 95% Cl 0.61–0.95, p<0.001). The result of FOLFIRINOX versus nab-paclitaxel + gemcitabine had no benefit (HR 0.91, 95% Cl 0.82–1.02, p>0.05). The main adverse events (AEs) targeted hematological toxicity and the gastrointestinal system, and included febrile neutropenia, a reduction in white blood cells and appetite, as well as diarrhea. Conclusion These findings indicated that FOLFIRINOX has potential benefits for the prognosis of patients with metastatic PC. Furthermore, there is no difference between the regimen of FOLFIRINOX and nab-paclitaxel + gemcitabine in this study. The application of FOLFIRINOX should be according to the actual situation of the patients and the experience of the doctors. Graphical abstract

【 授权许可】

Unknown